Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAURA adjuvant osimertinib versus placebo in resected EGFR-mutated NSCLC
NL-OMON45003Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Mar 2016; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON45003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45003.